Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Palantirs strong Q3 results and raised outlook were followed by a selloff, as traders focused on slower contract bookings and the stocks lofty valuation despite accelerating AI and commercial demand. The community is split between bulls viewing the dip as an overreaction and bears questioning whether future growth can justify the premium.

Shopifys Q3 report sparked a sharp selloff as GMV and subscription revenue fell short of expectations, despite strong profit and revenue growth; traders are debating whether the reaction is an overreaction or reflects a high valuation and moderating growth.

A record quarter and raised fiscal-year revenue outlook, backed by strong orders and AI-chip testing demand, are driving AEHRs sharp advance. Traders are celebrating the beat-and-raise and potential AI growth while debating the stocks rich valuation and whether the volatile rally will hold.

Organigrams agreement to acquire Aurora, topping Curaleafs rival bid, is driving the sharp move in ACB. Traders are debating whether Curaleaf could counterbid and how much upside remains under the announced deal, while others view the acquisition as settled.

Madrigals Q3 results, led by strong Rezdiffra sales growth and its first profitable quarter, are driving attention. Bulls point to commercial momentum and the potential to expand treatment into more advanced MASH, while skeptics question the stocks muted reaction, elevated spending and lack of guidance as investors await clinical-outcomes data.

Marvells all-stock acquisition of Lumentum is driving attention, with traders focused on potential shareholder dilution, the deals size and timing, and analyst downgrades amid the selloff. The community is mostly critical of the near-term risks, while some see strategic value in combining Marvells chips and networking with Lumentums optical technology for AI data centers.

A report that nonprofit Usona had filed for a psilocybin treatment for major depression sparked concern about competition and a sharp selloff, though traders dispute how confirmed the filing is and whether it threatens Compasss treatment-resistant-depression focus and commercial infrastructure. The debate is tempered by Compasss update that COMP360s FDA submission is nearing completion, with some traders viewing Usonas potential entry as manageable and others concerned about timing and market share.

Blocks upcoming Q3 earnings are the main focus, with traders watching gross-profit growth and Cash App lending alongside concerns about rising loan losses and a recent Morgan Stanley downgrade. Sentiment is divided between hopes for a beat and frustration that the stock remains weak despite bullish outlooks and analyst upgrades.

Upstarts quarterly results have sparked debate: traders point to stronger revenue, earnings and loan activity, while a more cautious outlook is cited as a reason the stock remains under pressure. Bears focus on debt, funding and interest-rate risks; bulls argue improving profitability and high short interest could support a rebound.

Pfizers quarterly results topped expectations and its full-year outlook was raised, but shares drew a muted-to-negative reaction. Traders are debating whether growth in newer launched and acquired products and cost cuts can offset declining COVID-related sales, patent-cliff concerns, and pressure on overall revenue.